MATTHEW FLYNN: Open Payments
NPI 1760618292 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$444 in 24 payments from 7 companies in 2025. Trend: 2023 $336 · 2024 $474 · 2025 $444
Food & beverage: $444
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 13 | $213 |
| Mallinckrodt Hospital Products Inc. | 3 | $75 |
| Merck Sharp & Dohme LLC | 3 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| ABBVIE INC. | 1 | $33 |
| 3B Medical, Inc. | 1 | $17 |
| Electromed, Inc. | 1 | $16 |
Products named: TRELEGY ELLIPTA, ACTHAR, ZERBAXA, TEFLARO, AIRSUPRA, TEZSPIRE, LUNA, NUCALA.
Industry payments across MS — which companies pay providers there.
